• 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
  • In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
  • Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
  • The following is a list of some of the commonly used adjuvant chemotherapy for breast cancer: CMF: cyclophosphamide, methotrexate, and 5-fluorouracil. (wikipedia.org)
  • FAC (or CAF): 5-fluorouracil, doxorubicin, cyclophosphamide. (wikipedia.org)
  • FEC: 5-fluorouracil, epirubicin and cyclophosphamide. (wikipedia.org)
  • This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. (jnccn.org)
  • Her treatment included Mohs paste application, together with chemotherapy (four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, and four cycles of docetaxel). (biomedcentral.com)
  • Many studies have reported anthracycline-based regimens increase the benefits compared to cyclophosphamide, methotrexate, and fluorouracil combinations. (kjco.org)
  • 10 ] compared the oncologic outcome of the various regimens in adjuvant CTx (cyclophosphamide, methotrexate, and fluorouracil combination, anthracycline-based regimens, taxane-anthracycline-based regimens, dose-dense taxane-anthracycline-based regimens). (kjco.org)
  • The pre-planned three-year interim analysis of a randomised, prospective trial compared adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for the treatment of early breast cancer with the standard, non-capecitabine regimen (docetaxel, epirubicin, cyclophosphamide and fluorouracil). (med-chemist.com)
  • Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. (hemonc.org)
  • She was started on 5 fluorouracil, epirubicin and cyclophosphamide (FEC) chemotherapy with gosarelin (Zoladex) and recombinant human granulocyte-colony stimulating factor, G-CSF, (Filgrastim) support. (biomedcentral.com)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • Patients with HER2-low breast cancer may have a new treatment option, the drug trastuzumab deruxtecan (T-DXd) , according to a study led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi, who presented the findings at this year's American Society of Clinical Oncology (ASCO) meeting. (knowbreastcancer.org)
  • Comparative real-world outcomes for patients with HER2-positive (HER2+) breast cancer receiving adjuvant trastuzumab outside of clinical trials are lacking. (jnccn.org)
  • This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. (roche.com)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
  • The ShortHER trial randomised 1254 patients with HER2+ early breast cancer to chemotherapy plus 9 weeks vs 1 year adjuvant trastuzumab. (ctimeetingtech.com)
  • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (hemonc.org)
  • Adjuvant trastuzumab in HER2-positive breast cancer. (hemonc.org)
  • Neratinib: A tyrosine kinase inhibitor approved for the extended adjuvant treatment of patients with early-stage Her2Neu-positive breast cancer, following adjuvant trastuzumab-based therapy. (medscape.com)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • I find it hard to know what to do for that patient because if they ended up having, [for example], 1.2-cm HER2-positive cancer that was node negative, you take them straight to surgery and they could get away with just TH [paclitaxel, trastuzumab]. (targetedonc.com)
  • She was referred for Portocath insertion after 3 cycles of 2 weekly docetaxel for her ongoing taxane/trastuzumab chemotherapy. (biomedcentral.com)
  • Herzuma (trastuzumab-pkrb) is a HER2 /neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer . (rxlist.com)
  • Tell your doctor and pharmacist if you are taking or have ever received certain cancer chemotherapy medications such as daunorubicin (Cerubidine), doxorubicin (Doxil), idarubicin (Idamycin), mitoxantrone (Novantrone), cyclophosphamide (Cytoxan), or trastuzumab (Herceptin). (medlineplus.gov)
  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per- Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). (revistarevisionesencancer.com)
  • CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. (revistarevisionesencancer.com)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. (trillium.de)
  • The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
  • TAC: Taxotere (docetaxel), Adriamycin (doxorubicin), and cyclophosphamide. (wikipedia.org)
  • Taxotere is a chemotherapy drug that was approved by the FDA in 1999 for the treatment of some types of small cell lung cancer. (lawstreetcapital.com)
  • Patients that are filing lawsuits against Sanofi have been given the drug to treat breast cancer, since Taxotere has become the top prescribed chemotherapy drug for this disease. (lawstreetcapital.com)
  • Taxotere's growing popularity is due in part to the fact that Taxotere treatments are administered every three weeks, rather than the weekly schedule required by another breast cancer drug paclitaxel. (lawstreetcapital.com)
  • Patients and physicians tend to prefer the convenience of Taxotere, although paclitaxel is just as effective in treating breast cancer as its counterpart. (lawstreetcapital.com)
  • Many have stated they would have elected to use paclitaxel as their cancer treatment drug if they had been informed of the risk of permanent hair loss with Taxotere. (lawstreetcapital.com)
  • With minimal response to chemotherapy, she proceeded to transarterial hepatic chemo-embolisation with mitomycin C/gemcitabine and converted to docetaxel (Taxotere) after 2 cycles of FEC. (biomedcentral.com)
  • Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. (carcinogenesis.com)
  • 2 First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer O'Shaughnessy J et al. (slideplayer.com)
  • Exploratory Ki-67 analysis suggested benefit of capecitabine in patients with more highly proliferative cancers (data not shown). (slideplayer.com)
  • 65 years old T x 3 → CEF x 3 (n = 745) T = docetaxel CEF = cyclophosphamide, epirubicin, 5-FU TX = capecitabine, docetaxel CEX = cyclophosphamide, epirubicin, capecitabine Joensuu H et al. (slideplayer.com)
  • Med-Chemist: Capecitabine combination therapy reduces early breast cancer recurrence. (med-chemist.com)
  • Capecitabine , is an orally-administered chemo therapeutic agent used in the treatment of metastatic breast and colorectal cancers. (med-chemist.com)
  • Recently, Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabin. (med-chemist.com)
  • The analysis also found that patients taking the capecitabine-containing regimen were significantly less likely to have their cancer spread (distant metastasis) to another part of the body (a 36% reduction in risk was observed). (med-chemist.com)
  • This is the first phase III randomised trial to report efficacy of capecitabine combination therapy in the adjuvant treatment of early breast cancer. (med-chemist.com)
  • See metastatic breast cancer. (wikipedia.org)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • Its being used (& FDA approved) in the treatment of adjuvant in colorectal cancer , metastatic colorectal cancer and Metastatic breast cancer - used in combination with docetaxel, after failure of anthracycline-based treatment. (med-chemist.com)
  • [ 2 ] Abemaciclib, palbociclib, and ribociclib are approved for initial and second-line therapy of HR-positive advanced and metastatic breast cancer. (medscape.com)
  • If you've received a diagnosis of a stage 3 cancer and larger tumors, you may go straight to systemic treatment before getting surgery. (healthline.com)
  • Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors comprising various breast cancers (BCs) defined as the absence of the estrogen receptor (ER) and progesterone receptor with corresponding negativity for human epidermal growth factor receptor 2 (HER-2). (karger.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • Using genetic mouse-models, we and others identified the RANKL/RANK system as a key regulator of sex hormone, BRCA1 -mutation, and oncogene-driven breast cancer and we proposed that RANKL/RANK might be involved in the initiation of breast tumors. (oncotarget.com)
  • The best candidates for neoadjuvant chemotherapy are patients with ER-negative and/or Her2Neu-positive expressing tumors, whose pathologically complete response (pCR) rates can approach 65% (in Her2Neu-positive cancers) and predict long-term survival. (medscape.com)
  • The CDK4/6 inhibitor abemaciclib (Verzenio) has been approved for use in hormone receptor (HR)-positive, Her2Neu-negative early breast cancer, for patients who have high-risk, node-positive disease and whose tumors have a Ki-67 score of ≥20%, as determined by a US Food and Drug Administration (FDA)-approved test. (medscape.com)
  • We propose that antiprogestins have the potential to enhance the efficacy of chemotherapy in breast tumors with a high PRA/PRB ratio. (oncotarget.com)
  • Because men have very little breast tissue, it is easier for men and health care professionals to feel small masses (tumors). (rxwiki.com)
  • In women with operable early breast cancer, taxane-containing adjuvant chemotherapy regimens have been found to improve overall survival and disease-free survival. (wikipedia.org)
  • Genotyping for the CYP19A1 rs1008805 polymorphism was performed for 287 females with hormone receptor (HR)‑positive early breast cancer, and potential associations were evaluated between CYP19A1 rs1008805 genotypes and disease‑free survival (DFS). (spandidos-publications.com)
  • In conclusion, the homozygous minor allele (GG) of CYP19A1 rs1008805 was identified to be significantly associated with an inferior clinical outcome of hormone therapy in postmenopausal hormone receptor‑positive patients with early breast cancer. (spandidos-publications.com)
  • 6 FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer Joensuu H et al. (slideplayer.com)
  • Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (revistarevisionesencancer.com)
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (revistarevisionesencancer.com)
  • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. (revistarevisionesencancer.com)
  • Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/ USOR 07132, and NSABP B-49 (NRG Oncology). (revistarevisionesencancer.com)
  • Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. (revistarevisionesencancer.com)
  • Chemotherapy-induced alopecia (CIA) affects the majority of patients receiving chemotherapy (CT) for early breast cancer. (plkinhibitors.com)
  • Consecutive early breast cancer patients admitted to Istituto Oncologico Veneto who were recommended to receive neoadjuvant or adjuvant CT, were eligible to undergo scalp cooling during the CT administration within this study. (plkinhibitors.com)
  • These results overall suggest that the use of scalp cooling is effective in preventing alopecia in the majority of early breast cancer patients receiving neoadjuvant or adjuvant CT, especially for patients undergoing a taxane-based non-anthracycline regimen. (plkinhibitors.com)
  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. (asitri.com)
  • By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines. (wikipedia.org)
  • Epirubicin is in a class of medications called anthracyclines. (medlineplus.gov)
  • Your age, the stage of the cancer, and any other health problems will all be taken into consideration before deciding on a chemo regimen. (healthline.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
  • In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
  • Methods An online survey was conducted among breast surgeons from the Spanish Society of Surgery (AEC), Spanish Surgical Oncology Society (SEOQ), Spanish Breast Cancer Surgeons Society (AECIMA) and Spanish Gynecology and Obstetrics Society (SEGO). (unav.edu)
  • Based on this evidence, guidelines published by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer state that when the overall risk of FN is 20% or greater, especially on "dose dense" regimens, primary prophylaxis with G-CSFs is justified [ 10 , 13 ]. (hindawi.com)
  • During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer. (targetedonc.com)
  • Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy - evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). (trillium.de)
  • Women with stage I-III, hormone receptor-positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada, were included. (jnccn.org)
  • There are various kinds of invasive cancers with cells lacking progesterone and estrogen receptors and no increase in the protein named HER2 on the surface. (healthresource4u.com)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
  • HealthDay News) - For patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the addition of bevacizumab to neoadjuvant chemotherapy improves the pathological complete response (pCR), according to two studies published in the January 26 issue of the New England Journal of Medicine . (cancertherapyadvisor.com)
  • Participants with untreated HER2-negative breast cancer were randomly allocated to treatment with epirubicin and cyclophosphamide followed by docetaxel, with or without concomitant bevacizumab. (cancertherapyadvisor.com)
  • Harry D. Bear, MD, PhD, from the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh, and colleagues investigated the efficacy of adding bevacizumab to neoadjuvant chemotherapy regimens for the treatment of HER2-negative breast cancer. (cancertherapyadvisor.com)
  • Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens inWomen With ERBB2/HER2-Negative Breast Cancer- The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. (revistarevisionesencancer.com)
  • For more information, see Breast Cancer , HER2 Breast Cancer , and Breast Cancer Treatment Protocols . (medscape.com)
  • You'll see that ER-positive, HER2- positive cancers tend to have recurrences a bit later than the ER-negative, HER2-positive cancers. (targetedonc.com)
  • Doctors only use chemotherapy for prostate cancer if it spreads outside of the prostate and if hormone therapy is unsuccessful. (medicalnewstoday.com)
  • Breast cancer is the number one cancer diagnosed amongst South African women with a 1 in 29 lifetime risk [ 2 , 3 ], while prostate cancer is the most prevalent in men [ 4 ]. (hindawi.com)
  • That approval has since been expanded to include treatment for head and neck cancer, gastric cancer, breast cancer and prostate cancer. (lawstreetcapital.com)
  • Prostate cancer is the most frequently diagnosed cancer in men and is responsible for approximately 41,000 deaths in the United States annually (Parker, S. L., et al. (justia.com)
  • Early stage, organ-confined, prostate cancer is often managed with surgery or radiation therapy until the patient dies from unrelated causes. (justia.com)
  • Hormone-Refractory-Prostate Cancer (HRPC), a non curable cancer type, is the second leading cause of cancer deaths in men in the US. (justia.com)
  • Direct correlation between resistance to chemotherapy and activation of PKB was shown in several prostate cancer cell lines and in human tumorogenic tissues, and elevation of PKB levels in prostate tumor tissues, is clinically associated with HRPC (Yongde et al. (justia.com)
  • Though studies have examined the cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prostate cancer, few have compared the cost-effectiveness of adjuvant goserelin to adjuvant chemotherapy alone in premenopausal breast cancer. (biomedcentral.com)
  • Gunter von Minckwitz, MD, from the German Breast Group in Neu-Isenburg, and colleagues investigated the efficacy and safety of adding bevacizumab to neoadjuvant chemotherapy in 1,948 patients with early-stage breast cancer. (cancertherapyadvisor.com)
  • Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. (jnccn.org)
  • Breast cancer chemotherapy refers to the use of cytotoxic drugs (chemotherapy) in the treatment of breast cancer. (wikipedia.org)
  • This article discusses some of the most common chemotherapy medications for use during cancer treatment. (medicalnewstoday.com)
  • Most cancer types have standard protocols that a doctor can follow when beginning treatment. (medicalnewstoday.com)
  • Doctors may start with a combination of docetaxel and prednisone, which is a steroid-based treatment. (medicalnewstoday.com)
  • Cancer can often be effectively treated with local therapies like surgery and radiation, without systemic treatment. (healthline.com)
  • The B-Raf proto-oncogene (BRAF V600E ) gene mutation has been identified in a variety of malignancies, but no evidence of the efficacy of vemurafenib treatment in BRAF V600E mutant breast cancer (BC) has been reported. (karger.com)
  • In triple-negative breast cancer, the usual systemic treatment is chemotherapy. (karger.com)
  • Treatment of breast cancer depends on type of cancer and the stage and involves chemotherapy , radiation or surgery. (healthresource4u.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • Chemotherapy (chemo), hormone treatment, targeted therapy, and immunotherapy drugs can reach cancer cells almost anywhere in the body. (knowbreastcancer.org)
  • What is the most successful cancer treatment? (knowbreastcancer.org)
  • Any cancer treatment can be used as a primary treatment, but the most common primary cancer treatment for the most common types of cancer is surgery . (knowbreastcancer.org)
  • If your cancer is particularly sensitive to radiation therapy or chemotherapy, you may receive one of those therapies as your primary treatment. (knowbreastcancer.org)
  • Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase Ill Study. (uni-koeln.de)
  • Here are drugs explicitly approved by the FDA for treatment of some cancers. (callaix.com)
  • For locally advanced breast cancer, Mohs chemosurgery, in addition to multidisciplinary treatment, is useful. (biomedcentral.com)
  • For decades, 5-year tamoxifen administration was the gold standard for the adjuvant endocrine treatment of breast cancer ( 9 ). (spandidos-publications.com)
  • Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed. (justia.com)
  • Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. (trillium.de)
  • There is clinical and experimental evidence suggesting that antiprogestins might be used for the treatment of selected breast cancer patients. (oncotarget.com)
  • Despite efforts to develop novel therapeutic anticancer agents to block specific signaling pathways, chemotherapy is still the gold standard for advanced breast cancer treatment. (oncotarget.com)
  • however, LCIS is associated with about a 5% 5-y risk and a 20-30% lifetime risk of developing invasive breast cancer, which may be ipsilateral or contralateral and may be ductal or lobular in origin[6] Pleomorphic LCIS is a LCIS variant that warrants special consideration in that treatment should include excision to negative margins. (medscape.com)
  • Epirubicin may cause serious or life-threatening heart problems at any time during your treatment or months to years after your treatment has ended. (medlineplus.gov)
  • Your doctor will order tests before and during your treatment to see if your heart is working well enough for you to safely receive epirubicin. (medlineplus.gov)
  • Possible mechanisms for gram for breast cancer in southern Sweden issued 1991, pre- recurrence after treatment are low initial drug sensitivity or menopausal lymph node positive (N+) breast cancer patients an acquired drug resistance. (lu.se)
  • In order to achieve a more effec- were recommended postoperative radiation and adjuvant tive and individualised chemotherapeutic treatment of breast chemotherapy. (lu.se)
  • 85% for adjuvant FEC-D affects breast cancer survival. (jnccn.org)
  • Triple-negative breast cancer is regarded as the most aggressive breast malignancy, which contributes to worse disease-free survival and overall survival. (karger.com)
  • With close to over 3.1 million American breast cancer survivors in the US, breast cancer and survival has risen in the US for different races and a worse survival rate for certain communities. (healthresource4u.com)
  • With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
  • Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. (revistarevisionesencancer.com)
  • Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. (revistarevisionesencancer.com)
  • Also, PKB is overexpressed in 15% of ovarian cancers, 12% of pancreatic cancers and 3% of breast cancers, and was shown to produce a survival signal that protects cells from apoptosis thus contributing to resistance to chemotherapy. (justia.com)
  • Major Cancer and Leukemia Group B (CALGB) chemotherapy clinical trials have consistently shown that chemotherapy produces significantly better disease-free and overall survival, particularly in patients with ER-negative disease. (medscape.com)
  • Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
  • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. (trillium.de)
  • Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. (trillium.de)
  • Many different types of breast cancer are there which vary in terms of the spreading or metastasis to different body tissues. (healthresource4u.com)
  • Esophageal cancer is a malignant disease with a poor prognosis and is one of the most common causes of cardiac metastasis. (bvsalud.org)
  • Generally, tumor size and axillary lymph node metastasis status are the most important prognostic factors for breast cancer patients. (kjco.org)
  • Adjuvant therapy for breast cancer is designed to treat any potential micrometastatic disease, or breast cancer cells that have escaped the breast and regional lymph nodes but have not yet established an identifiable metastasis. (medscape.com)
  • 12 Kindler syndrome is associated with some malignant tumours like skin, larynx, oropharynx, bladder etc. 11 Kindlin 1 is a regulator of TGF-beta and through this mechanism it plays a role in pulmonary metastasis of breast cancer and lung cancer. (org.pk)
  • tell your doctor and pharmacist if you are allergic to epirubicin, daunorubicin (Cerubidine, DaunoXome), doxorubicin (Doxil), idarubicin (Idamycin), any other medications, or any of the ingredients in epirubicin injection. (medlineplus.gov)
  • Over the last three decades, the number of breast cancer cases has increased worldwide ( 1 ) to become the most likely cause of cancer mortality and morbidity in females ( 2 ). (spandidos-publications.com)
  • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. (trillium.de)
  • Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. (trillium.de)
  • Nevertheless, for premenopausal women with breast cancer, protection of ovarian function is important in order to maintain quality of life (QoL) and fertility. (biomedcentral.com)
  • There are some malignant disease associations like synchronous or metachronous ovarian, colonic and endometrial tumours with Breast cancer. (org.pk)
  • The most common are breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2), both of which significantly increase the risk of both breast and ovarian cancer in women. (rxwiki.com)
  • Neoadjuvant chemotherapy Neoadjuvant chemo is given before surgery to slow the growth of a fast growing cancer or to shrink the size of a larger breast cancer. (wikipedia.org)
  • So, neoadjuvant chemo is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too big to be removed by surgery, which can then be removed with less extensive surgery. (wikipedia.org)
  • Palliative chemotherapy Palliative chemo is used to control (but not cure) the cancer in settings in which the cancer has spread beyond the breast and localized lymph nodes. (wikipedia.org)
  • In these cases, chemo is used as adjuvant therapy , or to prevent cancer from returning after the tumor has been removed. (healthline.com)
  • Not all chemo drugs cause hair loss , but most of those mentioned above for early stage cancer will have that side effect. (healthline.com)
  • What are the side effects of chemo pills for breast cancer? (knowbreastcancer.org)
  • Some examples of oral chemo drugs for breast cancer include: cyclophosphamide. (knowbreastcancer.org)
  • Can you cure breast cancer without chemo? (knowbreastcancer.org)
  • Chemo agents for specific cancers in PDF format. (callaix.com)
  • Chemotherapy and other systemic therapies are the primary treatments for patients with unresectable, locally advanced breast cancer. (biomedcentral.com)
  • Here, we report two cases of locally advanced breast cancer, for which the patients underwent radical surgery after a combination of systemic therapy and Mohs chemosurgery. (biomedcentral.com)
  • Patients with ER-positive, Her2Neu-negative locally advanced breast cancer (LABC) are unlikely to achieve a pCR from currently available chemotherapy. (medscape.com)
  • 1] For breast cancer, chemotherapy drugs are given into a vein (intravenously) or by mouth as tablets or capsules (orally). (wikipedia.org)
  • There are several main types of chemotherapy drugs that doctors use to target different types of cancer. (medicalnewstoday.com)
  • How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies? (ox.ac.uk)
  • Filling in the gaps: Reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. (trillium.de)
  • Axillary dissection may be considered in cases of node-positive breast cancer. (medscape.com)
  • Breast cancer is characterized by the growth of a malignant tumor arising from breast cells. (healthresource4u.com)
  • However, in patients with breast cancer, there is little reported experience with the application of Mohs paste for the purpose of tumor reduction. (biomedcentral.com)
  • Sometimes, breast cancer can spread to lymph nodes under the arm or around the collar bone and cause a lump or swelling there, even before the original tumor in the breast tissue is large enough to be felt. (rxwiki.com)
  • Epirubicin is used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. (medlineplus.gov)
  • Most adjuvant breast cancer chemotherapy regimens do not routinely require growth factor support except for those associated with a high incidence of bone marrow suppression and infection. (wikipedia.org)
  • The following sections look at some common chemotherapy medications for each common type of cancer. (medicalnewstoday.com)
  • These medications are used to treat breast cancer that's estrogen- or progesterone-responsive in those who've undergone menopause. (knowbreastcancer.org)
  • Anagen effluvium is sometimes referred to as chemotherapy-induced alopecia as it can be triggered by medications typically used to treat cancer. (ro.co)
  • Epirubicin may increase your risk for developing leukemia (cancer of the white blood cells), especially when it is given in high doses or together with certain other chemotherapy medications. (medlineplus.gov)
  • Epirubicin should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (medlineplus.gov)
  • Epirubicin comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications. (medlineplus.gov)
  • Multiple chemotherapeutic agents may be used in combination to treat patients with breast cancer. (wikipedia.org)
  • They may try cabazitaxel if the first combination does not treat the cancer. (medicalnewstoday.com)
  • This survey, addressed to breast cancer surgeons in Spain, has the objective of assessing current clinical trends on axillary staging of cN + patients treated with NAC. (unav.edu)
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. (revistarevisionesencancer.com)
  • Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (lu.se)
  • First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without. (slideplayer.com)
  • Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: A systematic review. (trillium.de)